WSLHD
Skip navigation
Please use this identifier to cite or link to this item: https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9008
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsilimigras, D. I.-
dc.contributor.authorEndo, Y.-
dc.contributor.authorRatti, F.-
dc.contributor.authorMarques, H. P.-
dc.contributor.authorCauchy, F.-
dc.contributor.authorLam, Vincent W. T.-
dc.contributor.authorPoultsides, G. A.-
dc.contributor.authorPopescu, I.-
dc.contributor.authorAlexandrescu, S.-
dc.contributor.authorMartel, G.-
dc.contributor.authorKitago, M.-
dc.contributor.authorGuglielmi, A.-
dc.contributor.authorHugh, T.-
dc.contributor.authorAldrighetti, L.-
dc.contributor.authorGleisner, A.-
dc.contributor.authorShen, F.-
dc.contributor.authorEndo, I.-
dc.contributor.authorPawlik, T. M.-
dc.date.accessioned2024-03-11T00:58:02Z-
dc.date.available2024-03-11T00:58:02Z-
dc.date.issued2024-
dc.identifier.citationAnnals of Surgical Oncology 31(4):2568-2578, 2024-
dc.identifier.urihttps://wslhd.intersearch.com.au/wslhdjspui/handle/1/9008-
dc.description.abstractINTRODUCTION: Immune dysregulation may be associated with cancer progression. We sought to investigate the prognostic value of perioperative lymphopenia on short- and long-term outcomes among patients undergoing resection of hepatocellular carcinoma (HCC).METHODS: Patients undergoing resection of HCC between 2000 and 2020 were identified using an international database. The incidence and impact of perioperative lymphopenia [preoperative, postoperative day (POD) 1/3/5], defined as absolute lymphocyte count (ALC) <1000/muL, on short- and long-term outcomes was assessed.RESULTS: Among 1448 patients, median preoperative ALC was 1593/muL [interquartile range (IQR) 1208-2006]. The incidence of preoperative lymphopenia was 14.0%, and 50.2%, 45.1% and 35.6% on POD1, POD3 and POD5, respectively. Preoperative lymphopenia predicted 5-year overall survival (OS) [lymphopenia vs. no lymphopenia: 49.1% vs. 66.1%] and 5-year disease-free survival (DFS) [25.0% vs. 41.5%] (both p < 0.05). Lymphopenia on POD1 (5-year OS: 57.1% vs. 71.2%; 5-year DFS: 30.0% vs. 41.1%), POD3 (5-year OS: 57.3% vs. 68.9%; 5-year DFS: 35.4% vs. 42.7%), and POD5 (5-year OS: 53.1% vs. 66.1%; 5-year DFS: 32.8% vs. 42.3%) was associated with worse long-term outcomes (all p < 0.05). Patients with severe lymphopenia (ALC <500/muL) on POD5 had worse 5-year OS and DFS (5-year OS: 44.7% vs. 54.3% vs. 66.1%; 5-year DFS: 27.8% vs. 33.3% vs. 42.3%) [both p < 0.05], as well as higher incidence of overall (45.5% vs. 25.3% vs. 30.9%; p = 0.013) and major complications (18.2% vs. 3.4% vs. 4.5%; p < 0.001) versus individuals with moderate (ALC 500-1000/muL) or no lymphopenia following hepatectomy for HCC. After adjusting for competing risk factors, prolonged lymphopenia was independently associated with higher hazards of death [hazard ratio (HR) 1.38, 95% CI 1.11-1.72] and recurrence (HR 1.22, 95% CI 1.02-1.45). CONCLUSION: Perioperative lymphopenia had short- and long-term prognostic implications among individuals undergoing hepatectomy for HCC. Copyright � 2024. Society of Surgical Oncology.-
dc.titlePerioperative Lymphopenia is Associated with Increased Risk of Recurrence and Worse Survival Following Hepatectomy for Hepatocellular Carcinoma-
dc.typeJournal Article-
dc.identifier.doihttps://dx.doi.org/10.1245/s10434-023-14811-7-
dc.subject.keywordsCarcinoma, Hepatocellular-
dc.subject.keywordsHepatectomy-
dc.subject.keywordsLiver Neoplasms-
dc.subject.keywordsRetrospective Studies-
dc.subject.keywordsLymphopenia-
dc.identifier.journaltitleAnnals of Surgical Oncology-
dc.identifier.departmentSurgery-
dc.contributor.wslhdLam, Vincent W. T.-
dc.identifier.pmid38180707-
dc.identifier.facilityWestmead-
Appears in Collections:Westmead Hospital 2019 - 2024

Files in This Item:
There are no files associated with this item.


Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.